Lima-Morales René, Méndez-Hernández Pablo, Flores Yvonne N, Osorno-Romero Patricia, Sancho-Hernández Christian Ronal, Cuecuecha-Rugerio Elizabeth, Nava-Zamora Adrián, Hernández-Galdamez Diego Rolando, Romo-Dueñas Daniela Karola, Salmerón Jorge
Secretaría de Salud de Tlaxcala, Dirección General, Tlaxcala, Mexico.
Secretaría de Salud de Tlaxcala, Dirección de Atención Especializada a la Salud, Tlaxcala, Mexico; Unidad de Investigación Epidemiológica y en Servicios de Salud, Delegación Morelos, Instituto Mexicano del Seguro Social, Blvd. Benito Juárez No. 31, Colonia Centro, Cuernavaca, Morelos, Mexico; Universidad Autónoma de Tlaxcala, Facultad de Ciencias de la Salud, Tlaxcala, Mexico.
Int J Infect Dis. 2021 Apr;105:598-605. doi: 10.1016/j.ijid.2021.02.014. Epub 2021 Feb 10.
There is an urgent need for effective treatments to prevent or attenuate lung and systemic inflammation, endotheliitis, and thrombosis related to COVID-19. This study aimed to assess the effectiveness of a multidrug-therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid ("TNR4" therapy) to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico.
A comparative effectiveness study was performed among 768 confirmed SARS-CoV-2 cases aged 18-80 years, who received ambulatory care at the Ministry of Health of Tlaxcala. A total of 481 cases received the TNR4 therapy, while 287 received another treatment (comparison group). All participants received home visits and/or phone calls for clinical evaluation during the 14 days after enrollment.
Nearly 85% of cases who received the TNR4 recovered within 14 days compared to 59% in the comparison group. The likelihood of recovery within 14 days was 3.4 times greater among the TNR4 group than in the comparison group. Patients treated with TNR4 had a 75% and 81% lower risk of being hospitalized or death, respectively, than the comparison group.
TNR4 therapy improved recovery and prevented the risk of hospitalization and death among ambulatory COVID-19 cases.
迫切需要有效的治疗方法来预防或减轻与新型冠状病毒肺炎（COVID-19）相关的肺部和全身炎症、内皮炎症及血栓形成。本研究旨在评估由伊维菌素、阿奇霉素、孟鲁司特和乙酰水杨酸组成的多药疗法（“TNR4”疗法）预防墨西哥特拉斯卡拉州非住院COVID-19病例住院和死亡的有效性。
对768例年龄在18至80岁之间、在特拉斯卡拉州卫生部接受门诊治疗的确诊严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病例进行了一项比较有效性研究。共有481例病例接受了TNR4疗法，而287例接受了另一种治疗（对照组）。所有参与者在入组后的14天内均接受了家访和/或电话随访以进行临床评估。
接受TNR4疗法的病例中近85%在14天内康复，而对照组为59%。TNR4组在14天内康复的可能性是对照组的3.4倍。接受TNR4治疗的患者住院或死亡风险分别比对照组低75%和81%。
TNR4疗法改善了非住院COVID-19病例的康复情况，并预防了住院和死亡风险。
